Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 5,000 shares of the business's stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $19.09, for a total value of $95,450.00. Following the transaction, the chief executive officer directly owned 922,892 shares in the company, valued at $17,618,008.28. The trade was a 0.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Samuel Kintz also recently made the following trade(s):
- On Friday, September 19th, Samuel Kintz sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.25, for a total value of $20,250.00.
- On Tuesday, August 19th, Samuel Kintz sold 590 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $11,800.00.
- On Monday, August 18th, Samuel Kintz sold 10,393 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.02, for a total value of $208,067.86.
- On Thursday, July 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.52, for a total value of $281,500.00.
Enliven Therapeutics Stock Down 4.8%
Shares of ELVN stock traded down $0.96 during trading on Friday, reaching $18.96. 2,310,053 shares of the company's stock were exchanged, compared to its average volume of 523,887. Enliven Therapeutics, Inc. has a twelve month low of $13.30 and a twelve month high of $30.03. The firm's fifty day moving average price is $20.11 and its 200-day moving average price is $19.67.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. As a group, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.
Institutional Trading of Enliven Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its position in shares of Enliven Therapeutics by 194.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company's stock worth $106,000 after buying an additional 3,490 shares during the last quarter. Duquesne Family Office LLC bought a new stake in shares of Enliven Therapeutics during the 2nd quarter worth $9,288,000. BNP Paribas Financial Markets lifted its position in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock worth $75,000 after buying an additional 930 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Enliven Therapeutics by 20.0% during the 2nd quarter. Bank of America Corp DE now owns 24,508 shares of the company's stock worth $492,000 after buying an additional 4,078 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its position in shares of Enliven Therapeutics by 150.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 59,244 shares of the company's stock worth $1,188,000 after buying an additional 35,582 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
ELVN has been the topic of a number of research reports. HC Wainwright upped their price objective on Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a report on Wednesday, July 2nd. The Goldman Sachs Group initiated coverage on Enliven Therapeutics in a report on Monday, June 16th. They issued a "buy" rating and a $37.00 price objective on the stock. Finally, Robert W. Baird upped their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a report on Monday, June 16th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $41.20.
Read Our Latest Report on ELVN
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
